Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares hit a new 52-week low during trading on Thursday . The company traded as low as $3.34 and last traded at $3.42, with a volume of 6948 shares trading hands. The stock had previously closed at $4.22.
The firm has a market cap of $4.47 million, a P/E ratio of -0.10 and a beta of 1.30.
Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Friday, November 9th. The company reported ($5.70) EPS for the quarter, beating analysts’ consensus estimates of ($6.10) by $0.40. Research analysts expect that Tonix Pharmaceuticals Holding Corp will post -23.5 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/4001416/tonix-pharmaceuticals-tnxp-reaches-new-1-year-low-at-3-34.html.
Tonix Pharmaceuticals Company Profile (NASDAQ:TNXP)
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population.
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.